Esperion Therapeutics Inc. had been working with the FDA in an attempt to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients, a population the US agency has been very cautious about in the past.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?